Table of Contents
ISRN Ophthalmology
Volume 2013, Article ID 384134, 6 pages
Clinical Study

Subconjunctival Bevacizumab Injection in Glaucoma Filtering Surgery: A Case Control Series

1Department of Ophthalmology, Maisonneuve-Rosemont Hospital, 5415 Boulevard de l’ Assomption, Montreal, QC, Canada H1T 2M4
2Ophthalmology Service, Department of Surgery, Centre Hospitalier Université de Sherbrooke, Hôtel Dieu, 580 Bowen Sud, Sherbrooke, QC, Canada J1G 2E8

Received 8 January 2013; Accepted 21 January 2013

Academic Editors: B. V. Bui, M. Nakazawa, and L. Pierro

Copyright © 2013 Jing Wang and Paul Harasymowycz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aims. To describe the use of subconjunctival bevacizumab (SCB) injection in the combined cataract and glaucoma filtering surgery (GFS). Methods. Retrospective comparative case series. Thirty eyes of twenty-eight patients who had GFS followed by SCB injection as part of post-operative management were included (Group SCB). The types of GFS included trabeculectomy and non-penetrating glaucoma surgery (NPGS) with mitomycin-C. Outcome measures included the reduction of intraocular pressure (IOP) and medications. Age-matched patients who had the same types of surgery without SCB were selected as a control group (Group C). Results. The types of GFS were: combined cataract surgery and NPGS (SCB: 20; C: 24), phacotrabeculectomy (SCB: 6; C: 3), NPGS (SCB: 3; C: 2) and trabeculectomy alone (SCB: 1; C: 1). The average follow-up time was 16.9 (±8.2) months in the SCB group and 19.6 (±11.5) months in the controls. 1.25 mg of bevacizumab was injected on average 14.1 (range: 3–42) days post-GFS. The mean IOP decreased from 21.9 (±9.8) to 11.9 (±4.7) mmHg in the controls and from 19.6 (±8.9) to 14.0 (±4.7) mmHg in the SCB group. There was no statistically significant difference between the two groups ( ). Complications included three cases of branch vein occlusion in the SCB group. Conclusions. SCB did not result in better outcome in term of IOP reduction. Clinicians should monitor its side effects in glaucoma patients.